GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report)'s stock price dropped 6.6% during mid-day trading on Wednesday . The stock traded as low as $95.62 and last traded at $93.93. Approximately 103,628 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 619,638 shares. The stock had previously closed at $100.59.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the company. The Goldman Sachs Group lifted their price objective on GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a report on Wednesday, February 19th. TD Cowen boosted their price target on GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $72.33.
Get Our Latest Stock Report on WGS
GeneDx Stock Down 2.3 %
The firm has a market capitalization of $2.59 billion, a price-to-earnings ratio of -47.04 and a beta of 1.91. The firm has a fifty day moving average price of $87.28 and a 200 day moving average price of $73.92. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.
GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The firm had revenue of $95.64 million during the quarter, compared to the consensus estimate of $82.24 million. Sell-side analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.
Insider Buying and Selling at GeneDx
In other news, CEO Katherine Stueland sold 51,420 shares of GeneDx stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $94.48, for a total value of $4,858,161.60. Following the completion of the sale, the chief executive officer now directly owns 1,720 shares of the company's stock, valued at approximately $162,505.60. This trade represents a 96.76 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin Feeley sold 35,506 shares of the business's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $93.82, for a total value of $3,331,172.92. Following the sale, the chief financial officer now owns 2,472 shares of the company's stock, valued at approximately $231,923.04. The trade was a 93.49 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 183,032 shares of company stock worth $17,007,198. 27.30% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On GeneDx
Several institutional investors have recently modified their holdings of the business. MCF Advisors LLC boosted its stake in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after acquiring an additional 182 shares during the last quarter. Sterling Capital Management LLC boosted its position in shares of GeneDx by 877.8% in the 4th quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock worth $27,000 after purchasing an additional 316 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of GeneDx during the fourth quarter worth $28,000. Lazard Asset Management LLC bought a new stake in GeneDx in the fourth quarter valued at about $35,000. Finally, Comerica Bank acquired a new position in GeneDx in the fourth quarter valued at about $50,000. Institutional investors and hedge funds own 61.72% of the company's stock.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
See Also
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
